drugset
drugset / Trial / NCT02078648

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

NCT02078648 ↗

Phase 1/2 Completed 74 enrolled Stemline Therapeutics, Inc.
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and efficacy of SL-701 as a treatment for recurrent glioblastoma multiform (GBM).

Timeline

Start
2014-05
Primary completion
2017-09-01
Completion
2018-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject SL-701 Vaccine 1 ml Subcutaneous
Background Bevacizumab Monoclonal antibody 10 mg/kg Intravenous
Background Hiltonol Other / unclassified 1.6 mg Intramuscular
Background Imiquimod Other / unclassified 125 mg Topical
Background sargramostim Protein / enzyme biologic 150 ug Subcutaneous

Indications

adult glioblastoma